A new type of molecular imaging procedure may be capable of detecting the presence of beta-amyloid, a protein linked to Alzheimer’s disease. This preliminary research is conducted by Avid Radiopharmaceuticals. The study provides evidence that a molecular imaging procedure can identify beta-amyloid pathology in the brain, a development that can help to identify Alzheimer’s disease. Florbetapir-PET imaging combines florbetapir F 18, a diagnostic chemical that binds to beta-amyloid, with a PET scan. The researchers used this technique to measure the beta-amyloid levels of 35 patients near the end of their lives, and compared this with beta-amyloid levels after death as determined by autopsy. An analysis of images and other data indicated a correlation between florbetapir-PET images and the levels of beta-amyloid pathology at autopsy. In addition, the Florbetapir-PET scans matched the autopsy results 96 percent of the time.